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Abstract 
 
Background:  Chronic  Kidney  Disease  (CKD)  is  one  of  the  most  severe  diseases  worldwide.  In 
patients affected by CKD, a progressive destruction of the nephrons is observed not only in structural 
but also in functional level. Atherosclerosis is a progressive disease of large and medium-sized arteries. 
It is characterized by the deposition of lipids and fibrous elements and is a common complication of the 
uremic syndrome because of the coexistence of a wide range of risk factors. High blood pressure, 
anaemia, insulin resistance, inflammation, high oxidative stress are some of the most common factors 
that  cause  cardiovascular  disease  and  atherogenesis  in  patients  suffering  from  End  Stage  Kidney 
Disease (ESRD). At the same time, the inflammatory process constitutes a common element in the 
apparition and development of CKD. A wide range of possible causes can justify the development of 
inflammation  under  uremic  conditions.  Such  causes  are  oxidative  stress,  oxidation,  coexistent 
pathological conditions as well as factors that are due to renal clearance techniques. 
Patients in ESRD and coronary disease usually show increased acute phase products. Pre-inflammatory 
cytokines, such as IL-6 and TNF-a, and acute phase reactants, such as CRP and fibrinogen, are closely 
related. The treatment of chronic inflammation in CKD is of high importance for the development of 
the disease as well as for the treatment of cardiovascular morbidity.  
Conclusions:  The  treatment  factors  focus  on  the  use  of  renin-angiotensic  system  inhibitors, 
acetylsalicylic acid, statins and anti-oxidant treatment in order to prevent the action of inflammatory 
cytokines that have the ability to activate the mechanisms of inflammation. 
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Introduction 
 
CKD is one of the most severe public health 
disorders worldwide with complications such 
as renal failure, cardiovascular disorders and 
early  death  (Harrison  2005;  Levey  et  al. 
2005,  Theofilou  2011a,  2011b).  CKD  is  a 
chronic  situation  including  irreversible, 
structural  or  functional  nephron 
abnormalities.  CKD  pathophysiology  is 
related  to  the  progress  of  the  disease.  As 
CDK  causes  chronic  damage,  the  renal 
function as a whole diminishes progressively 
and irreversibly. As a result, at end stage, a 
limited number of increased-charge nephrons 
accomplish the processes of renal function. 
The pathogenicity of CKD results from the 
combinations of the detrimental effects that 
include  water  and  electrolytes  homeostasis 
disorders,  reduced  removal  of  soluble 
organic  substances  and  reduced  hormone 
production.  The  Glomerural  Filtration  Rate 
(GFR) is the amount of water filtered by the 
glomerulus in the capillary tuft in a particular 
period and is an index that controls kidney 
function (Vander et al. 2001; Kalantar-Zadeh 
et  al.  2006;  Pragna  et  al.  2008).  GFR 
reduction  <60  ml/min/1,73  m
2  of  the  body 
surface  for  ≥3  months  determines  CKD 
(National Kidney Foundation 2002; Levey et 
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ascending  scale  according  to  its  severity 
depends on GFR values (Levey et al. 2005). 
The loss of endogenous renal function leads 
to a uremic syndrome and in the long run the 
patient  might  be  in  need  of  renal  function 
substitution (Harrison 2005; Kalantar-Zadeh 
et al 2006; Pragna et al. 2008). There are two 
types  of  disorders  depending  on  the 
pathophysiologic  mechanism  of  the 
syndrome: Disorders as a consequence of the 
accumulation of protein metabolism products 
and  disorders  as  a  consequence  of  renal 
failure,  such  as  homeostasis  of  water  and 
electrolytes as well as hormonic disorders. 
The  uremic  syndrome  (TABLE  B)  can  be 
treated to a certain extent with renal function 
extracorporeal  substitution.  However,  some 
of  the  disorders  may  not  respond  to  the 
treatment,  they  may  even  deteriorate 
(Harisson 2005). 
 
Table A. Classification of chronic kidney diseases in order of increasing severity 
Stage  Description of chronic 
kidney disease 
GFR(ml/min/1.73 
m
2) 
Associated 
terminology 
1  Kidney damage with normal 
or high glomerular filtration 
rate 
≥90  Albuminuria, 
proteinuria, hematuria 
2  Kidney damage with mildly 
low glomerular filtration rate 
60-89  Albuminuria, 
proteinuria, hematuria 
3  Moderate glomerular 
filtration rate decrease  
30-59  Chronic/early renal 
insufficiency 
4  Severe glomerular filtration 
rate decrease 
15-29  Chronic/ late renal 
insufficiency 
5  Kidney failure  <15  End-stage renal 
disease, uremia 
 
 
CKD is associated with two risk factors with 
a bidirectional relation leading to increased 
morbidity and mortality in patients with end-
stage  renal  disease  (ESRD).  Those  are: 
cardiovascular  disease  (CVD)  and  the 
inflammation pathogenic mechanisms. Apart 
from  the  improved  modern  renal  dialysis 
techniques, morbidity and mortality indexes 
for  ESRD  patients  remain  quite  high. 
Cardiovascular disease (CVD) is one of the 
main reasons of this effect with its presence 
being  further  enhanced  by  coexisting 
situations.  The  inflammation  is  another 
factor that is responsible not only for CKD 
evolution  but  also  for  the  appearance  of 
CVD.  The  inflammation  mechanism 
enhances  CVD  pathogenicity  together  with 
other  clinical  findings  of  the  uremic 
syndrome. 
 
Epidemiology 
 
Cardiovascular diseases are main morbidity 
and  death  causes  in  CKD  patients,  and 
especially  to  ESRD  ones,  with  an  annual 
frequency of 9%. Death caused by CVD is 
by  10-20  times  more  frequent  in  patients 
with CKD than in the rest of the population. 
In CKD patients, the risk of death after CVD 
is  
 
 
much  higher  than  the  risk  of  death  after  a 
hemodialysis.  
This  shows  that  CKD  patients  differ  from 
other  patients  when  it  comes  to 
cardiovascular  vulnerability,  as  C-Reactant 
Protein  (CRP)  inflammation  index  is 
increased.  It  is  estimated  that  30-50%  of 
those patients  show  activated  inflammatory 
response. The increased (>8-10 mg/L) levels 
of  CRP  serum  result  in  atherosclerosis 
(Locatelli  et  al.  2003;  Nalbandi  2008; 
Stefanadis 2008). 
 
Atherosclerosis Pathogenicity 
 
Atherosclerosis  is  a  disease  of  big  and 
middle  muscle  arteries  where  atheromatous 
plaques are formed as a result of the complex 
accumulation  of  cells  and  extracellular 
substances in the endothelium and the tunica 
intima  of  the  vessels.  Even  though  the 
inflammation is a non-traditional risk factor 
for atherosclerosis, it has proved to play an 
important  role  in  the  appearance  and  the 
progress of the atheromatous process. There International Journal of Caring Sciences     2013   January-April Vol 6  Issue 1 
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are  many  different  theories  on 
atherosclerosis  pathophysiology.  The 
dominant one is endothelial function disorder 
resulting  from  the  existence  of  risk  factors 
such  as  dyslipidemia,  diabetes,  smoking, 
high  blood  pressure  (HBP)  and 
hyperhomocysteinemia  bacterial  and  viral 
infections  (mainly  Chlamydia  pneumonia, 
Helicobacter  pylori  and  cytomegalovirus) 
(Fertakis  1988;  Bocker  et  al.  2007; 
Papasteriadi 2008). 
The  inflammation  is  the  common 
denominator in a series of cardiovascular risk 
factors such as hyperlipidemia, HBP etc. In 
case  the  inflammatory  process  is  not 
successfully  treated,  the  atheromatous 
lesions  may  evolve  silently  to  obstructive 
lesion  and  may  lead  to  rupture  of  the 
atheromatous  plaque  and  acute  clinical 
syndromes (Caimi et al. 2005; Bocker et al. 
2007; Papasteriadi 2008). 
 
Inflammation And CKD 
 
Inflammation  is  the  initial  response  of  the 
body  to  harmful  stimuli  such  as  infection, 
injury  or  toxic  damage.  It  is  a  protective 
physiological  response  that  destroys 
pathogenic  factors  that  have  caused  the 
damage, as well as damaged tissues. It is a 
mechanism  of  exceptional  importance  and 
constitutes  an  integral  part  of  our  defense 
system.  Under  normal  conditions  the 
inflammation  is  acute  (Pragna  et  al.  2008; 
Roit et al. 2004).  
A cascade of biochemical events propagates 
and  matures  the  inflammatory  response. 
Prolonged  inflammation,  known  as  chronic 
inflammation  may  bear  destructive 
consequences  for  the  organism.  The 
inflammation  index  are  closely  associated 
with  anorexia,  increased  reduction  of  the 
protein  rate  by  skeletal  muscles  and  other 
tissues, loss of adipose and muscle tissues, 
hypoalbuminemia  and  hypercatabolism, 
endothelial  dysfunction  and  atherosclerosis. 
As  a  result,  inflammatory  process  is  a 
common element in CKD. About 30-60% of 
individuals undergoing extrarenal dialysis in 
Europe  and  North  America  show  an 
increased  inflammation  index  (Kalantar-
Zadeh  et  al.  2006;  Axelsson  et  al.  2007; 
Pragna et al. 2008). 
The inflammation is an important parameter 
for CKD appearance and evolution. Research 
has  shown  that  patients  undergoing  renal 
dialysis  techniques  and  protein  energy 
malnutrition tend to show increased levels of 
inflammatory  index  and  pro-inflammatory 
cytokines  such  as  interleukin  1  (IL-1), 
interleukin 6 (IL-6) and TNF.  
Those  indexes  are  proportional  to  the 
anorexia levels in such patients (Vander et al. 
2001). Other CKD factors contributing to the 
inflammation are high levels of acute-phase 
CRP,  advanced  enzymic  glycation  end 
products  (AGEs)  and  advanced  oxidation 
protein products (AOPPs) (Kalantar-Zadeh et 
al. 2006; Axelsson et al. 2007; Pragna et al. 
2008), (14), (13). 
A wide range of possible causes can justify 
the  development  of  inflammation  under 
uremic  conditions  such  as  oxidative  stress, 
oxidation, coexisting pathological situations 
and  factors  due  to  the  renal  dialysis 
techniques (TABLE C), (Kalantar-Zadeh et 
al. 2006). 
 
Cytokine Role 
 
Cytokines  play  an  integral  part  in  the 
inflammation  process.  During  the 
inflammation, there is an imbalance between 
pro-inflammatory  and  anti-inflammatory 
cytokines.  Uremic  toxins  in  CKD  activate 
pro-inflammatory cytokines independently of 
whether the patient is at a stage before renal 
dialysis  or  already  undergoing  a  treatment 
technique  (hemodialysis  or  peritoneal 
dialysis).  The  disturbance  of  this  balance 
contributes to atherogenesis thus promoting 
the development of CVD. Diminished renal 
function increases cytokine concentration in 
the  organism  even  in  cases  of  membrane 
bioincompatibility in dialysis techniques. At 
the same time, oxidative stress, oxidation and 
coexisting  pathological  situations  promote 
inflammatory action (Stenvinkel et al. 2002; 
Jacobs  et  al.  2004;  Kalantar-Zadeh  et  al. 
2006). However, there is no specific way to 
control the severity rate of the inflammation 
in  CKD  patients.  During  an  inflammatory 
response  there  is  an  increase  in  positive 
acute-phase  proteins,  such  as  CRP  and 
ferritin,  and  a  reduction  in  negative  acute-
phase  proteins,  such  as  albumin  or 
transferring  (Kalantar-Zadeh  et  al.  2006; 
Axelsson et al. 2007; Pragna et al. 2008).  
CRP  is  a  positive  acute-phase  protein  that 
increases during systemic  inflammation. Its International Journal of Caring Sciences     2013   January-April Vol 6  Issue 1 
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composition takes place in the liver and its 
levels  show  the levels  of tissue  damage  or 
the  extent  of  the  inflammatory  response. 
Normally  its  value  is  about  <1mg/L. 
Increased  CRP  quantities  imply  that  an 
inflammatory response is taking place. High 
CRP  levels  in  healthy  patients  have  been 
identified  as  an  important  risk  factor  for 
CVD, coronary disease and specific bacterial 
or  viral  infections.  At  ESRD,  CRP  levels 
remain  >5mg/l  for  >3  months.  In  case  of 
chronic  inflammation,  it  remains  at  high 
levels for years thus signaling an increased 
risk for atheromatous cardiovascular disease. 
In CKD and residual renal functions (RRF) 
patients,  CRP  is  between  5-50  mg/L.  CRP 
has  been  isolated  from  the  inflammatory 
damage of atheromatic vessels and a slight 
increase  constitutes  important  risk  and 
disease  index  (14  MIA).  CRP  levels  also 
show  an  increased  production  of  pro-
inflammatory cytokines IL-1, IL-6 and TNF-
a  making  them  a  very  important  index  in 
CKD (Jacobs et al. 2004). 
Interleukin-6 (IL-6) is a pleiotropic cytokine 
with a dominant role.  
It regulates the inflammatory responses and 
the  composition  of  hepatic  acute-phase 
proteins. In healthy patients, IL-6 mRNA is 
expressed at low levels by various cell types 
including  peripheral  lymphocytes,  spleen, 
liver,  kidney,  and  intestine.  During  an 
infection,  injury  or  immune  challenge, 
almost  every  tissue  and  cell  type  of  the 
organism composes and expresses IL-6.  
Moreover,  IL-6  launches  an  increased 
production  of  hepatic  acute-phase  proteins 
that regulating the composition of CRP. This 
differentiates  it  from  IL-1  and  TNF-a 
cytokines  that  reduce  production  of  such 
proteins by hepatocytes (Pragna et al. 2004; 
Kalantar-Zadeh  et  al.  2008).  Moreover, 
insulin stimulates IL-6 gene expression. 
Interleukin  1  is  a  multifunctional  cytokine. 
There are two types of interleukin: lL-1a and 
IL-1b  with  unclear  effects  in  biological 
activity.  Interleukin  is  involved  in  the 
regulation  of  cell  division  and  cell 
differentiation and is a highly inflammatory 
cytokine (Stenvinkel et al. 2000; Pragna et 
al. 2008).  
TNF-a  is  produced  by  active  monocyte 
macrophages  and  is  of  great importance in 
inflammation pathogenesis, septic shock and 
tissue injury. TNF-a  comes from the liver. 
Intrinsic  and  extrinsic  factors  such  as 
bacteria,  viruses,  parasites  and  tumors  are 
able to cause its production (Vander 2001).  
It contributes to the progress of endothelial 
dysfunction  and  increases  insulin  reaction. 
At  the  same  time,  it  also  reduces 
apolipoprotein  E  secretion.  (Mavromatidis 
2008 ).  
Together  with  the  other  pro-inflammatory 
cytokines,  TNF-a  promotes  protein 
catabolism and inhibit albumin, pro-albumin 
and transferrin composition. 
Studies  have  shown  that  pro-inflammatory 
cytokines  have  atherogenic  properties. 
Firstly, IL-6 increased levels are a stimulus 
for soluble intracellular adhesion molecule 1 
(sICAM-1)  that  acts  as  a  mediator  in 
leukocyte adhesion and leukocyte migration 
on the endothelial surface.  
Moreover,  IL-6  promotes  atherosclerosis 
through  various  metabolic,  endothelial  and 
coagulant  mechanisms.  It  is  not  just  an 
atheromatous index. It has been proved that 
increased IL-6 expression is involved in the 
formation  of  the  fibrous  plaques  in  the 
atheromatous process (Zyga et al. 2011). 
 
Insulin  Resistance 
 
Insulin resistance is an ESRD parameter and 
it has been proved that hypoglycaemia and 
hyperglycaemia  contribute  to  early 
atherogenesis  in  ESRD  patients.  In  ESRD, 
insulin  resistance  may  result  from  various 
factors such as reduced renal catabolism of 
regulatory  proteins,  metabolic  oxidation, 
uremic  toxins,  protein  catabolism  products, 
reduced  physical  activity,  anemia,  chronic 
inflammation,  hypothrepsia.  Insulin 
resistance syndrome is an independent factor 
for  cardiovascular  mortality  prevision  in 
ESRD.  
Pro-inflammatory  and  pro-atherogenic 
cytokines  like  IL-6  and  TNF-a  factor, 
accumulate  as  residual  renal  function 
deteriorates.  
TNF-a action reduces glucose storing in cells 
after insulin action, while inactivity enhances 
insulin  sensitivity.  The  inflammation  is 
associated  with  various  insulin  resistance 
factors.  
In elderly non-diabetic patients, mild chronic 
inflammation and high sICAM-1 levels have 
been  found,  as  well  as  a  disproportional International Journal of Caring Sciences     2013   January-April Vol 6  Issue 1 
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relation between insulin sensitivity and IL-6 
levels.  Consequently,  low  level  chronic 
inflammation  contributes  to  the  relation 
between  insulin  resistance  and  CVD  risk 
(Mavromatidis  2008;  Kalantar-Zadeh  et  al. 
2008). 
   
 
 
 
 
 
 
TABLE B. FINDINGS OF CLINICAL PATHOLOGY OURAIMIAS 
Fluid and electrolyte disorders  Neuromuscular 
disorders 
Skin disorders 
Increase (dilation) and volume 
contraction 
Fatigue   Paleness  
Hypernatremia and 
hyponatremia 
Sleep disorders   Hyperpigmentation  
Hyperkalemia and hypokalemia  Headache   Itching  
Metabolic acidosis  Mental deficiency  Ecchymosis   
Hyperfosfatiaimia  Lethargy   Uremic salt deposition in the 
skin on the form of ice 
(uremic frost) 
Hypocalcemia   Astirixia    Gastrointestinal disorders 
Endocrine - Metabolic 
disorders 
Muscle irritability  Anorexia  
Secondary hyperparathyroidism  Peripheral neuropathy  Nausea and vomiting  
Adynamic osteomalacia  Syndrome of “restless 
legs” 
Uremic exhalation  
Osteomalacia due to deficiency 
of vitamin-D 
Paralysis   Gastroenteritis  
Intolerance to carbohydrates  Myoclonus    Peptic ulcer 
Hyperuricemia    Seizures   Gastrointestinal bleeding 
Hypertriglykeridaimia   Coma   Hepatitis  
Elevated levels of lp(a)  Muscle cramps  Idiopathic ascites  
Decreased levels of high density 
lipoprotein 
Syndrome breaking the 
balance in dialysis 
Peritonitis  
Nutritional disorder caused by 
inadequate intake of protein- 
energy 
Myopathy   Haematological and 
immunological disorders 
Slowdown in growth and 
development 
Cardiovascular and 
pulmonary disorders 
Anemia  
Leucopenia   
Amenorrhea   Arterial hypertension  Lemfokyttaropenia   
Infertility and sexual dysfunction  Congestive heart 
failure and pulmonary 
edema 
Bleeding  
Hypothermia  Worsening 
atherosclerosis 
Increased susceptibility in 
infections 
Β2-microglobulin deposition  Hypotension and 
arrhythmias 
Splenomegaly and 
hypersplenism  
Amyloidosis   Calcification of 
vascular 
Decreased levels of C International Journal of Caring Sciences     2013   January-April Vol 6  Issue 1 
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TABLE C. Causes of chronic inflammation in Chronic Kidney Disease 
Α. Causes of inflammation due to CKD or decreased GFR 
1.  Decreased clearance of pro- inflammatory cytokines  
2.  Volume overload with or without endotoxemia 
3.  Accumulation of uremic toxins 
4.  Oxidative stress (e.g. oxygen radicals) 
5.  Carbonyl stress( pentoside and advanced glycation products) 
6.  Decreased levels of antioxidants (vitamin Ε, vitamin C, carotenoids, 
selenium, glutathione) 
7.  Deteriorating protein- energy nutritional state and food intake 
Β.   Coexistence of cormobid conditions 
1.  Increased prevalence of cormobid conditions (cardiovascular disease, 
diabetes, advanced age, obesity, dyslipidemia, etc.) 
2.  Remnants from previous allograft transplantation of solid organa 
3.  Inflammatory diseases with kidney involvement (with HIV disease or SLE), 
chronic obstructive urinary ouropatheia 
C.   Additional inflammatory factors related to dialysis treatment 
       Ι.    Hemodialysis  
1.  Exposure to dialysis tubing 
2.  Dialysis membranes with decreased biocompability 
3.  Impurities in dialysis water and/ or dialysate 
4.  Back-filtration  or back- diffusion of contaminants 
5.  Foreign bodies (such as PTTE) in dialysis access grafts 
6.  Intravenous catheters 
       ΙΙ.   Peritoneal dialysis 
1.  Episodes of overt or latent peritonitis 
2.  PD-catheters as a foreign body and its related infections 
3.  Constant exposure to PD solution 
 
 
 
 
Treatment In CKD Statines 
 
Statines  show  important  anti-inflammatory 
action and reduce CRP levels independently 
from  their  impact  of  inhibiting  lipid 
composition.  They  are  also  connected  with 
reduced mortality levels in CKD patients that 
are due to heart diseases (Vander 2001).  
 
Αngiotensin-converting enzyme inhibitors 
(ACE inhibitors) 
 
They  have  anti-inflammatory  action  in  the 
general population and in patients suffering 
from ESRD and they are connected with a 
delay  in  the  progress  of  CKD,  thus 
improving  the  clinical  result  in  individuals 
suffering from the disease.  
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ACE inhibitors have the ability to suppress 
the production of certain cytokines, such as 
TNF-a or IL-1b, whereas in ESRD patients 
they  reduce  CRP  levels  (Vander  2001; 
Francesco et al. 2003; Nalmbandi 2008). 
 
Acetylsalicylic acid 
  
Acetylsalicylic  acid  reduces  CRP  and  IL-6 
levels  in  patients  with  coronary  disease. 
Moreover,  CRP  levels  seem  to  be  closely 
connected  to  myocardiac  infarction  risk 
reduction  with  the  use  of  aspirin. 
Consequently,  it  could  be  used  for  the 
treatment  of  the  chronic  inflammation  of 
CKD patients. 
 
Antioxidant treatment 
 
Vitamin E has anti-inflammatory action and 
its  administration  is  connected  with  a  low 
risk of cardiovascular mortality in patients at 
a dialysis. It has been claimed that vitamin E 
has  a  protective  role  against  the 
inflammatory process and atherosclerosis as 
it inhibits the action of protein kinase C and 
nuclear  factor  kappa-b.  Other  studies  have 
shown that when the dialysis filters contain 
vitamin  E,  oxidative  stress  is  reduced, 
whereas its use through dialysis membranes 
reduces myeloperoxidase release, suggesting 
a  lower  neutrophil  activation.  However, 
further research has to be conducted on the 
exact action and its relativity/connection to 
the inflammation and its parameters, as well 
as on atherosclerosis and its contribution to 
the  clinical  result  (Vander  2001; 
Mavromatidis 2008). 
Moreover,  the  use  of  biocompatible 
membrane  and  ultrapure  hemodialysis  can 
reduce hemodialysis-connected inflammation 
and  the  improvement  of  the  dialysis 
techniques  in  hemodialysed  patients  with 
inflammation  is  very  important.  Similarly, 
new  and  more  biocompatible  solvents  of 
peritoneal  dialysis  should  be  applied  in 
patients that show elements of inflammation 
(Kalantar-Zadeh  et  al.  2006;  Mavromatidis 
2008). 
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